Starace Vincenzo, Battista Marco, Brambati Maria, Cavalleri Michele, Bertuzzi Federico, Amato Alessia, Lattanzio Rosangela, Bandello Francesco, Cicinelli Maria Vittoria
Department of Ophthalmology, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Department of Ophthalmology, IRCCS San Raffaele Scientific Institute, Milan, ItalySchool of Medicine, Vita-Salute San Raffaele University, Milan, Italy.
Ther Adv Ophthalmol. 2021 Dec 5;13:25158414211055963. doi: 10.1177/25158414211055963. eCollection 2021 Jan-Dec.
The pathogenesis of diabetic macular edema (DME) is complex. Persistently high blood glucose activates multiple cellular pathways and induces inflammation, oxidation stress, and vascular dysfunction. Retinal ganglion cells, macroglial and microglial cells, endothelial cells, pericytes, and retinal pigment epithelium cells are involved. Neurodegeneration, characterized by dysfunction or apoptotic loss of retinal neurons, occurs early and independently from the vascular alterations. Despite the increasing knowledge on the pathways involved in DME, only limited therapeutic strategies are available. Besides antiangiogenic drugs and intravitreal corticosteroids, alternative therapeutic options tackling inflammation, oxidative stress, and neurodegeneration have been considered, but none of them has been currently approved.
糖尿病性黄斑水肿(DME)的发病机制复杂。持续的高血糖会激活多种细胞途径,并引发炎症、氧化应激和血管功能障碍。视网膜神经节细胞、大胶质细胞和小胶质细胞、内皮细胞、周细胞以及视网膜色素上皮细胞均参与其中。以视网膜神经元功能障碍或凋亡性丧失为特征的神经退行性变在早期就会发生,且独立于血管改变。尽管对DME所涉及的途径的认识不断增加,但可用的治疗策略仍然有限。除了抗血管生成药物和玻璃体内注射皮质类固醇外,针对炎症、氧化应激和神经退行性变的替代治疗方案也已被考虑,但目前均未获得批准。